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In order to control the spread of the SARS-CoV2 virus, many hospitals have prohibited or limited the 
scope of in-person clinical research assessments in accordance with regional restrictions. In this webinar, 
the American Neurological Association (ANA) interviewed Drs. Devin Brown, a stroke neurologist at 
University of Michigan; Jeffrey Cohen, a multiple sclerosis (MS) neurologist at Cleveland Clinic; and 
Lesli Skolarus, a stroke neurologist at University of Michigan. These physician scientists are conducting 
multicenter clinical trials and they discussed how they are adjusting their ongoing studies to follow 
current guidelines and assure participant and staff safety. Plans for future clinical trial modifications were 
also discussed. 
 
SAFETY CONCERNS AND OTHER CHALLENGES FACED WHILE CONDUCTING CLINICAL 
RESEARCH DURING THE COVID-19 OUTBREAK 
 
The panelists identified many universal challenges while conducting clinical research during the COVID-
19 outbreak, including: restrictions on in-person recruitment and outcome assessments, restrictions on 
specimen processing, strains on Institutional Review Boards to review protocol changes, and reluctance 
of study participants to come to medical facilities for research-related activities. The panelists 
acknowledged that sites across the United States are differentially impacted by COVID-19, resulting in 
different accommodations for each site in a multicenter trial.  
 
The panelists also discussed specific challenges encountered in their clinical trials. Dr. Skolarus is 
currently conducting a community-based mobile health technology intervention to reduce blood pressure 
(Reach Out)1. Because her trial recruits from the emergency department, Dr. Skolarus’ team faces 
recruitment challenges in a population with an undifferentiated risk of SARS-CoV2 exposure. In-person 
outcome assessments were not possible during Michigan’s Stay-at-Home order. In order to fulfill their 
commitment to enrolled participants, they transitioned to remote outcomes assessment via telephone.  In 
addition, Reach Out is transitioning to virtual screening and enrollment to avoid unnecessary study staff 
and participant exposure. Dr. Cohen’s study compares hematopoietic stem cell transplantation (HSCT) to 
highly effective disease modifying therapies in people with relapsing multiple sclerosis (MS) (BEAT-
MS)2. This trial includes collaborations with multiple departments, including interventional radiology for 
lumbar punctures and the transplant team for HSCT. These departments have their own regulations during 
the current outbreak, which have limited necessary testing and treatment administration. Dr. Cohen faces 
additional challenges as HSCT, and possibly highly effective disease modifying therapies, increase 
infection risk. In addition to instituting screening procedures and contact precautions for participants and 
staff, he has revised all consent forms to reflect potential COVID-19 risks.  Dr. Brown codirects a clinical 
trial to determine whether treatment of obstructive sleep apnea (OSA) with continuous positive airway 
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pressure (CPAP) in patients with stroke improves stroke recurrence or recovery (Sleep SMART)3. With 
the COVID-19 outbreak, Dr. Brown’s team paused in-person interactions including enrollments study-
wide for a period of time, and has provided guidance to mitigate the risk of potential viral transmission to 
household members of participants using CPAP. 
 
HOW TO DETERMINE WHICH ASPECTS OF A TRIAL CAN BE TRANSITIONED TO A VIRTUAL 
PLATFORM 
 
The panelists highlighted the need for validated, widely accepted virtual outcome measures to help 
maintain safety in clinical trials. They discussed their own strategies to modify ongoing and future clinical 
trials in detail. Sleep SMART already utilized a telemedicine platform for care management and could 
continue to collect outcome measures via telephone (such as the modified Rankin Scale-9Q)4. In contrast, 
Dr. Skolarus has adapted her study and highlighted a novel use of participants’ smart devices to assist 
with data collection. A primary outcome of Reach Out includes blood pressure readings at six and twelve 
months; to improve the validity of these assessments, the study team requests participants to text a non-
identifiable picture of the blood pressure cuff on their arm.  Finally, the Mellen Center for MS Treatment 
and Research has developed self-administered versions of MS outcomes that can be administered on a 
tablet or smart phone5. Validated telemedicine outcomes could be helpful in future clinical trials and 
present new opportunities to researchers. However, the panelists agreed that mixing validated in-person 
outcomes with unvalidated virtual outcomes could affect clinical trial interpretation and should be 
avoided, if possible.  
 
 
IMPACT OF COVID-19 ON FUTURE CLINICAL RESEARCH 
 
The COVID-19 pandemic will undoubtedly leave a lasting impact on clinical research. The panelists 
anticipated that future studies might include screening through electronic medical record-based 
algorithms and remote recruitment facilitated by e-consenting. In addition, study visits may transition to 
virtual assessments to maintain safety of participants and research staff. The panelists also expected 
newer technologies, like wearable devices, to be utilized more often for remote data collection. However, 
virtual outcomes introduce a risk of selection bias. The panelists noted that patients have unequal access 
to and familiarity with technology, including smart phones and computers. Therefore, researchers must 
exercise additional caution to ensure their studies prioritize inclusion of underserved populations. 
 
Scientists and physicians must also consider the impact of COVID-19 on current research. Dr. Cohen 
highlighted that physicians will have to grapple with unanticipated direct and indirect consequences of 
COVID-19 when interpreting trial results. For example, many neurologists may adjust their prescribing 
patterns to treat MS based on individual patient characteristics, the specific immunomodulatory effects of 
disease modifying therapies, and their need for infusion in a medical facility. In addition, the economic 
and mental health consequences of COVID-19 may affect demographic and quality of life outcomes . 
Several groups have outlined the impact of COVID-19 on research networks and ongoing clinical trials 
with blueprints for reinstitution of clinical trial enrollment6,7.  
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Overall, the panelists remained optimistic that aspects of future clinical research may benefit from the 
challenges faced during the current pandemic. New clinical trials that take advantage of the tools 
discussed above can address novel questions and reach a larger patient base. Although the reasons behind 
the shift are multifactorial, Dr. Skolarus noted increased participant retention after transitioning to virtual 
study visits. The panelists agreed that the scientific community needs to validate and reach consensus on 
preferred virtual outcome measures to power new trials. Dr. Skolarus reminds our audience that, while 
adjusting research trials can be challenging, adapting to our new research environment will be critical to 
ensuring the success of future studies. 
 
Suggested Supplemental Material 
The full-length version of the webinar can be reached at https://myana.org/education/ana-webinars or via 
the QR code 
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INTRODUCTION 
 
In order to control the spread of the SARS-CoV2 virus, many hospitals have prohibited or limited the 
scope of in-person clinical research assessments in accordance with regional restrictions. In this webinar, 
the American Neurological Association (ANA) interviewed Drs. Devin Brown, a stroke neurologist at 
University of Michigan; Jeffrey Cohen, a multiple sclerosis (MS) neurologist at Cleveland Clinic; and 
Lesli Skolarus, a stroke neurologist at University of Michigan. These physician scientists are conducting 
multicenter clinical trials and they discussed how they are adjusting their ongoing studies to follow 
current guidelines and assure participant and staff safety. Plans for future clinical trial modifications were 
also discussed. 
 
SAFETY CONCERNS AND OTHER CHALLENGES FACED WHILE CONDUCTING CLINICAL 
RESEARCH DURING THE COVID-19 OUTBREAK 
 
The panelists identified many universal challenges while conducting clinical research during the COVID-
19 outbreak, including: restrictions on in-person recruitment and outcome assessments, restrictions on 
specimen processing, strains on Institutional Review Boards to review protocol changes, and reluctance 
of study participants to come to medical facilities for research-related activities. The panelists 
acknowledged that sites across the United States are differentially impacted by COVID-19, resulting in 
different accommodations for each site in a multicenter trial.  
 
The panelists also discussed specific challenges encountered in their clinical trials. Dr. Skolarus is 
currently conducting a community-based mobile health technology intervention to reduce blood pressure 
(Reach Out)1. Because her trial recruits from the emergency department, Dr. Skolarus’ team faces 
recruitment challenges in a population with an undifferentiated risk of SARS-CoV2 exposure. In-person 
outcome assessments were not possible during Michigan’s Stay-at-Home order. In order to fulfill their 
commitment to enrolled participants, they transitioned to remote outcomes assessment via telephone.  In 
addition, Reach Out is transitioning to virtual screening and enrollment to avoid unnecessary study staff 
and participant exposure. Dr. Cohen’s study compares hematopoietic stem cell transplantation (HSCT) to 
highly effective disease modifying therapies in people with relapsing multiple sclerosis (MS) (BEAT-
MS)2. This trial includes collaborations with multiple departments, including interventional radiology for 
lumbar punctures and the transplant team for HSCT. These departments have their own regulations during 
the current outbreak, which have limited necessary testing and treatment administration. Dr. Cohen faces 
additional challenges as HSCT, and possibly highly effective disease modifying therapies, increase 
infection risk. In addition to instituting screening procedures and contact precautions for participants and 
staff, he has revised all consent forms to reflect potential COVID-19 risks.  Dr. Brown codirects a clinical 
trial to determine whether treatment of obstructive sleep apnea (OSA) with continuous positive airway 
pressure (CPAP) in patients with stroke improves stroke recurrence or recovery (Sleep SMART)3. With 
the COVID-19 outbreak, Dr. Brown’s team paused in-person interactions including enrollments study-
wide for a period of time, and has provided guidance to mitigate the risk of potential viral transmission to 
household members of participants using CPAP. 
 
HOW TO DETERMINE WHICH ASPECTS OF A TRIAL CAN BE TRANSITIONED TO A VIRTUAL 
PLATFORM 
 
The panelists highlighted the need for validated, widely accepted virtual outcome measures to help 
maintain safety in clinical trials. They discussed their own strategies to modify ongoing and future clinical 
trials in detail. Sleep SMART already utilized a telemedicine platform for care management and could 
continue to collect outcome measures via telephone (such as the modified Rankin Scale-9Q)4. In contrast, 
Dr. Skolarus has adapted her study and highlighted a novel use of participants’ smart devices to assist 
with data collection. A primary outcome of Reach Out includes blood pressure readings at six and twelve 
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months; to improve the validity of these assessments, the study team requests participants to text a non-
identifiable picture of the blood pressure cuff on their arm.  Finally, the Mellen Center for MS Treatment 
and Research has developed self-administered versions of MS outcomes that can be administered on a 
tablet or smart phone5. Validated telemedicine outcomes could be helpful in future clinical trials and 
present new opportunities to researchers. However, the panelists agreed that mixing validated in-person 
outcomes with unvalidated virtual outcomes could affect clinical trial interpretation and should be 
avoided, if possible.  
 
 
IMPACT OF COVID-19 ON FUTURE CLINICAL RESEARCH 
 
The COVID-19 pandemic will undoubtedly leave a lasting impact on clinical research. The panelists 
anticipated that future studies might include screening through electronic medical record-based 
algorithms and remote recruitment facilitated by e-consenting. In addition, study visits may transition to 
virtual assessments to maintain safety of participants and research staff. The panelists also expected 
newer technologies, like wearable devices, to be utilized more often for remote data collection. However, 
virtual outcomes introduce a risk of selection bias. The panelists noted that patients have unequal access 
to and familiarity with technology, including smart phones and computers. Therefore, researchers must 
exercise additional caution to ensure their studies prioritize inclusion of underserved populations. 
 
Scientists and physicians must also consider the impact of COVID-19 on current research. Dr. Cohen 
highlighted that physicians will have to grapple with unanticipated direct and indirect consequences of 
COVID-19 when interpreting trial results. For example, many neurologists may adjust their prescribing 
patterns to treat MS based on individual patient characteristics, the specific immunomodulatory effects of 
disease modifying therapies, and their need for infusion in a medical facility. In addition, the economic 
and mental health consequences of COVID-19 may affect demographic and quality of life outcomes . 
Several groups have outlined the impact of COVID-19 on research networks and ongoing clinical trials 
with blueprints for reinstitution of clinical trial enrollment6,7.  
 
Overall, the panelists remained optimistic that aspects of future clinical research may benefit from the 
challenges faced during the current pandemic. New clinical trials that take advantage of the tools 
discussed above can address novel questions and reach a larger patient base. Although the reasons behind 
the shift are multifactorial, Dr. Skolarus noted increased participant retention after transitioning to virtual 
study visits. The panelists agreed that the scientific community needs to validate and reach consensus on 
preferred virtual outcome measures to power new trials. Dr. Skolarus reminds our audience that, while 
adjusting research trials can be challenging, adapting to our new research environment will be critical to 
ensuring the success of future studies. 
 
Suggested Supplemental Material 
The full-length version of the webinar can be reached at https://myana.org/education/ana-webinars or via 
the QR code 
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